Opdivo (nivolumab), one of the earliest checkpoint inhibitors, has been approved by the US Food and Drug Administration for the first-line treatment of gastric cancer – the first immunotherapy for this indication. The approval also covers gastroesophageal junction cancer and oesophageal adenocarcinoma.
